



## BioCryst to Announce Fourth Quarter and Full Year 2017 Financial Results on February 27

February 20, 2018

RESEARCH TRIANGLE PARK, N.C., Feb. 20, 2018 (GLOBE NEWSWIRE) -- [BioCryst Pharmaceuticals, Inc.](http://www.biocryst.com) (NASDAQ:BCRX) announced today that its fourth quarter and full year 2017 financial results will be reported on Tuesday, February 27, 2018.

BioCryst will host a conference call and webcast at 11:00 a.m. Eastern Time to discuss financial results and to provide an update regarding the Company's clinical development programs. The call will be led by Jon P. Stonehouse, President & Chief Executive Officer, Thomas R. Staab II, Senior Vice President & Chief Financial Officer, and Dr. Bill Sheridan, Senior Vice President and Chief Medical Officer.

Links to a live audio webcast and replay of the presentation may be accessed on the BioCryst website events page at <http://investor.shareholder.com/biocryst/events.cfm>.

### About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals designs, optimizes and develops novel small-molecule medicines that address both common and rare conditions. BioCryst has several ongoing development programs including BCX7353, an oral treatment for hereditary angioedema, galidesivir, a potential treatment for filoviruses, and a preclinical program to develop oral Alk-2 inhibitors for the treatment of fibrodysplasia ossificans progressive (FOP). RAPIVAB® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, is BioCryst's first approved product and has received regulatory approval in the U.S., Canada, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing, as well as activities to support regulatory approvals in other territories. For more information, please visit the Company's website at [www.BioCryst.com](http://www.BioCryst.com).

This press release contains forward-looking statements, including statements regarding future results and achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Please refer to the documents BioCryst files periodically with the SEC and located at <https://biocryst.gcs-web.com/financial-information/sec-filings>.

BCRXW

CONTACT: Thomas Staab, BioCryst Pharmaceuticals, +1-919-859-7910



Source: BioCryst Pharmaceuticals, Inc.